I still expect LPTN to be the target of a reverse merger in due course. Investing in biotech companies with busted pipelines that are trading below net cash can be rewarding; however, achieving a gain that exceeds the opportunity cost depends to a large degree on luck.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”